21 total trials were performed, with each target velocity presented 7 times.
The social rejection and somatic pain tasks each consisted of two consecutively administered runs of eight trials (that is, 16 total trials).
To mitigate this concern, the present experiment included 280 total trials and we jittered the inter-trial-interval and the delay period between the response and feedback phase of each trial to optimize design efficiency.
In the visible condition, subjects' visibility ratings indicated that target images were partly or clearly perceived (percentage of total trials: visibility 1: 3.5% ± 3.0%; visibility 2: 18.5% ± 7.5%; visibility 3: 37.8% ± 5.4%; visibility 4: 45.4% ± 9.4%).
In a repeated-measures design spanning 6 days, females were housed with water bottles containing Red Bull, caffeine or water in a randomized order, and tested for VO2max twice while receiving each fluid (6 total trials).
Gratings were shown for a duration of 20 seconds per trial at two velocities (5° · s−1 and 10° · s−1) and two stimulus directions (right to left, or left to right) for two trials each, resulting in 8 total trials.
Probes in the non-matching condition (50% of total trials) were either the product of the cue numbers (strong cue-probe association), the multiple of either cue numbers (weak cue-probe association), or an arithmetically neutral number with respect to the cue numbers (no cue-probe association).
The entire task lasted for 10 min for each individual (roughly 75 total trials).
The initial test began with instructions and two practice trials, followed by 106 total trials (two of which were catch trials).
Data was processed automatically for artifacts using a moving window peak-to-peak method with the epoch length as the test period and window of 100 ms, resulting in less than 10%% of total trials being rejected.
This mapping resulted in an incredible amount of variability in change target/distractor scene combinations, with many presentations of each possible combination occurring across participants in the almost 26,000 total trials (75% change and 25% no-change trials, 999 trials per participant).
